Loading...
A phase I study of nintedanib combined with cisplatin/gemcitabine as first-line therapy for advanced squamous non-small cell lung cancer (LUME-Lung 3).
Forster, M Hackshaw, A De Pas, T Cobo, M Garrido, P Summers, Yvonne J Dingemans, A Flynn, M Schnell, D von Wangenheim, U
Forster, M
Hackshaw, A
De Pas, T
Cobo, M
Garrido, P
Summers, Yvonne J
Dingemans, A
Flynn, M
Schnell, D
von Wangenheim, U
Citations
Altmetric:
Abstract
There are limited treatment options for squamous non-small cell lung cancer (sqNSCLC) and prognosis remains poor. The safety and pharmacokinetics (PK) of nintedanib, a triple angiokinase inhibitor, plus cisplatin/gemcitabine as first-line treatment for advanced sqNSCLC patients, were evaluated.
Description
Date
2018-06
Publisher
Collections
Files
Keywords
Type
Article
Citation
A phase I study of nintedanib combined with cisplatin/gemcitabine as first-line therapy for advanced squamous non-small cell lung cancer (LUME-Lung 3). 2018, 120: 27-33 Lung Cancer